A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma

We investigated 2-weekly intravenous irinotecan combined with oral capecitabine in patients with advanced gastroesophageal adenocarcinoma. In phase I, doses were escalated in chemotherapy naïve or pretreated patients to establish maximum tolerated doses (MTD). In phase II, patients were treated at M...

Descripción completa

Detalles Bibliográficos
Autores principales: Burge, M E, Smith, D, Topham, C, Jackson, D P, Anthoney, D A, Halstead, F, Seymour, M T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361406/
https://www.ncbi.nlm.nih.gov/pubmed/16622464
http://dx.doi.org/10.1038/sj.bjc.6603084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361406/
https://www.ncbi.nlm.nih.gov/pubmed/16622464
http://dx.doi.org/10.1038/sj.bjc.6603084

Ejemplares similares